research 1..13 - American Chemical Society

Jun 14, 2018 - reduced cholinergic (α7 nAChR; alpha 7 nicotinic acetylcholine receptor) ... diseases including AD.4 It could be categorized into (a) m...
1 downloads 0 Views 2MB Size
Subscriber access provided by UNIVERSITY OF CONNECTICUT

Article

3,4-Dihydroxyphenylethanol Assuages Cognitive Impulsivity in Alzheimer’s Disease by Attuning HPA-axis via Differential Crosstalk of #7 nAChR with microRNA-124 and HDAC6 ArunSundar MohanaSundaram, Thukani Sathanantham Shanmugarajan, and Velayutham Ravichandiran ACS Chem. Neurosci., Just Accepted Manuscript • DOI: 10.1021/acschemneuro.7b00532 • Publication Date (Web): 14 Jun 2018 Downloaded from http://pubs.acs.org on June 17, 2018

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 56 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

ACS Chemical Neuroscience

1

3,4-Dihydroxyphenylethanol Assuages Cognitive Impulsivity in Alzheimer’s Disease by

2

Attuning HPA-axis via Differential Crosstalk of α7 nAChR with microRNA-124 and

3

HDAC6

4 5

Mohanasundaram ArunSundar†, Thukani Sathanantham Shanmugarajan†*, Velayutham

6

Ravichandiran‡

7 8



9

(VISTAS), Pallavaram, Chennai-600117, India.

Department of Pharmacology, School of Pharmaceutical Sciences, Vels University

10



11

Kolkata, India.

Director, National Institute of Pharmaceutical Education and Research (NIPER),

12 13

*

14

Dr. TS Shanmugarajan,

15

Department of Pharmacology,

16

School of Pharmaceutical Sciences,

17

Vels University (VISTAS),

18

Chennai 600117, India

19

[email protected]

20

+91-956-6049808

Corresponding author:

21 22 23 24 25

1 ACS Paragon Plus Environment

ACS Chemical Neuroscience 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 2 of 56

26

Abstract:

27

Cognitive impulsivity, a form of suboptimal cost-benefit decision making is an illustrious

28

attribute of an array of neurodegenerative diseases including Alzheimer’s Disease (AD).

29

In this study, delay discounting paradigm was used to assess the effect of 3,4-

30

dihydroxyphenylethanol (DOPET) on cognitive impulsivity—in an oA42i (oligomeric

31

amyloid β1–42 plus ibotenic acid) induced AD mouse model—using a non-spatial T-maze

32

task. The results depicted that oA42i administration elevated cognitive impulsivity,

33

whereas DOPET treatment attenuated the impulsive behavior and matched the choice

34

of the sham-operated controls. In addition, DOPET treatment has ameliorated the

35

anxiety-like behavior in the oA42i-challenged mice. Probing the molecular signaling

36

cascades underpinning these functional ramifications in the oA42i-challenged mice

37

revealed: reduced cholinergic (α7 nAChR; alpha 7 nicotinic acetylcholine receptor)

38

function, dysregulated HPA-axis (manifested by amplified glucocorticoid receptor

39

expression

40

neuroepigenetic (microRNA-124, HDAC6 (histone deacetylase 6), and HSP90 (heat-

41

shock protein 90) expressions) as well as nucleocytoplasmic (importin-α1 expression

42

and nuclear ultra-architecture) continuum. Nonetheless, DOPET administration

43

ameliorated these perturbations and the observations were in line with that of the sham-

44

operated mice. Further validation of the results with organotypic hippocampal slice

45

cultures (OHSCs) confirmed the in vivo findings. We opine that HPA-axis attunement by

46

DOPET might be orchestrated through α7 nAChR-mediated pathway. Based on these

47

outcomes, we posit that 3,4-dihydroxyphenylethanol might be a potential multimodal

48

agent for the management of cognitive impulsivity and neuromolecular quagmire in AD.

and

plasma

corticosterone

levels),

and

2 ACS Paragon Plus Environment

also

aberrations

in

the

Page 3 of 56 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

ACS Chemical Neuroscience

49 50

Keywords: 3,4-Dihydroxyphenylethanol, Alzheimer’s Disease, Cognitive impulsivity,

51

Cholinergic receptor, HPA-axis, Decision making, HDAC6, microRNA-124

52 53

INTRODUCTION

54

Alzheimer’s Disease (AD), the most common type of dementia, is a leading cause of

55

health crisis in the elderly, based on disabilities and morbidity across the globe. The

56

global prevalence of AD is expected to increase from 46.8 million in 2015 to about 131.5

57

million by 20501. Well above 95% of all the AD cases are non-familial and sporadic late

58

onset cases2. Formation of senile β-amyloid protein plaques, neurofibrillary tau-protein

59

tangles, neurodegeneration and cognitive impairment (e.g., sub-optimal decision

60

making) are the pathognomonics of Morbus Alzheimer3.

61 62

Impulsivity, a type of suboptimal cost-benefit decision making—broadly defined as the

63

tendency to act prematurely without foresight—is a facet of various neurodegenerative

64

diseases including AD4. It could be categorized into: (a) motor impulsivity (failure to

65

control inhibitory response), and (b) cognitive impulsivity (impulsive decision making)5.

66 67

Delay discounting (temporal discounting), an oft-reported measure of cognitive

68

impulsivity, involves subjectively discounting (devaluing) the rewards (benefit) by the

69

delay (cost) necessary to obtain them6. A seminal review by Vanderveldt et al.,

70

concluded that delay discounting is notably pervasive and shares a commonly evolved

71

decision making mechanism in humans and animal species.7

3 ACS Paragon Plus Environment

ACS Chemical Neuroscience 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 4 of 56

72 73

Investigation of the neural, neurochemical and epigenetic correlates underlying delay

74

discounting aids to discover potential pharmacotherapies for the management of

75

impulsivity in AD. Indubitably, stress is a critical etiological factor in AD vulnerability and

76

development. Heightened indices of stress engender in dysregulation of the

77

hypothalamic–pituitary–adrenal (HPA) axis, which is manifested through elevated

78

neurohormones, specifically glucocorticoids (GCs).8 Abnormally triggered glucocorticoid

79

receptor (GR) signaling/glucocorticoid hormones–primarily cortisol in humans and

80

corticosterone in rodents–have notorious implications on hippocampal structure. A study

81

by Brureau et al., showed that increased GCs observed in AD could be first a

82

consequence of amyloid toxicity and also HPA-axis dysfunction is linked with the

83

disruption of the GR nucleocytoplasmic shuttling9. In this line, Pineau et al., reported

84

that

85

concentrations of corticosterone, spatial memory dysfunction and hippocampus

86

apoptosis10. Hippocampus is more vulnerable to the pathological insults of amyloid beta

87

and elevated GCs in AD and the repercussions include remarkable hippocampus-

88

dependent memory deficits and impulsive decision making.5-7 Several lines of studies

89

have demonstrated the strong association between various facets of impulsivity and

90

AD4,14,15.

selective

glucocorticoid

receptor

modulators

reversed

the

high

plasma

91 92

In a study by Abela et al., the authors proposed that targeting the hippocampal circuitry

93

would be a potential strategy in the management of impulsive choice16. A recent report

94

showed that β-amyloid peptide is co-localized with alpha7 nicotinic acetylcholine

4 ACS Paragon Plus Environment

Page 5 of 56 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

ACS Chemical Neuroscience

95

receptor (α7 nAChR) in the senile plaque17. Besides, the study reported that interaction

96

between β-amyloid and α7 nAChR provokes neuronal apoptosis and diminution of the

97

α7 nAChR expression; but, α7 nAChR agonists could augment the learning and

98

memory potential.17 These reports imply that therapies targeting multimodal or

99

combinatory strategies are required for the management of AD.

100 101

A landmark study led by Fischer et al. accentuated that drugs regulating the

102

neuroepigenetic machinery (especially histone deacetylase (HDAC) inhibitors) stave-off

103

the cognitive deficits and ameliorate phenotypic outcomes in AD.18 Deficits in

104

neurotrophins like BDNF (brain-derived neurotrophic factor) subsequent to epigenetic

105

dysregulation is known to play a causal role in impulsive behavior.19 On the other hand,

106

therapeutics targeting BDNF restoration have shown positive outcomes in the

107

management of AD20,21. In congruence with these reports, our earlier study depicted

108

that BDNF expression and cognitive functions were reduced in the AD mice, whereas

109

hydroxytyrosol (3,4-dihydroxyphenylethanol (DOPET); a dopamine metabolite, and also

110

a polyphenol from olive oil) treatment ameliorated the reduced BDNF levels and

111

cognitive decline.22

112 113

More circumstantial evidences point to the causal link between disruption of importin-

114

mediated nucleocytoplasmic cargo trafficking and neuronal cell death as well as

115

cognitive impairment in AD.23,24 Importin-α1 (Imp-α1; karyopherin alpha 2; KPNA2) is a

116

nuclear import protein that plays a central role in the flow of genetic information and

117

multitude of other cellular activities. On the other hand, Imp-α1 has been shown to

5 ACS Paragon Plus Environment

ACS Chemical Neuroscience 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 6 of 56

118

partake in various pathological mechanisms leading to a gamut of diseases including

119

cancers, neurological disorders, and viral infections. 24,25

120 121

In this backdrop, the present study was embarked upon to investigate the putative

122

beneficial effects of DOPET on the cognitive impulsivity and anxiety, dysregulated HPA

123

axis, hippocampal cholinergic degeneration, and perturbations in neuroepigenetic and

124

nucleocytoplasmic shuttling circuitry in an animal model of oA42i (soluble oligomeric

125

amyloid β1–42 plus ibotenic acid)-induced AD. Our study marks one of the first attempts

126

to untangle the neuromolecular mechanisms linking dysregulated hippocampal

127

cholinergic-HPA

128

neuroeconomic task in an AD mouse model.

axis

and

sub-optimal

decision-making

on

a

T-maze

based

129 130

Organotypic hippocampal slice cultures (OHSCs) best recapitulate the complex three-

131

dimensional (3D) organization of the hippocampus and this model bridges the gap

132

between in vitro and in vivo models. Hence, to validate the in vivo experimental

133

outcomes and to further explore the neurotoxic and neuroprotective signaling

134

mechanisms of oA42i and DOPET respectively, we have used the OHSCs tool.

135 136

RESULTS AND DISCUSSION

137

DOPET treatment improved the impulsive decision making in the oA42i-

138

challenged mice

139

Cognitive impulsivity, an indicator of sub-optimal decision making, was significantly

140

increased in the oA42i-challenged mice (Figure 2B). This inference is based on the

6 ACS Paragon Plus Environment

Page 7 of 56 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

ACS Chemical Neuroscience

141

observation that during phase B (i.e. blocks 4-6, post-induction testing), oA42i mice has

142

depicted a reduced preference for HR, delayed by 10-s as opposed to the LR. The

143

results of phases A and B were included in a three-way ANOVA, with a between-

144

subjects factor of group and within-subject factors of phase and block. This analysis

145

revealed a significant group x phase interaction [F2,29 = 10.12; P < 0.05]. But, no

146

hindrance was observed in the optimal decision making among all the three mice

147

groups in the phase A (i.e. blocks 1-3, pre-induction testing). There was no effect of

148

block or any significant interaction involving block (all P > 0.40). Further analysis of the

149

group x phase interaction, using analysis of simple main effects, showed that there was

150

a significant group difference in phase B [F1,29 = 7.92; P < 0.05], but not in phase A (F